Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations

April 16, 2023 · Benzinga

Clinical-stage biopharma company atai Life Sciences 

ATAI-6.00%+ Free Alerts announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of proprietary R-ketamine, PCN-101.

Open-label, the trial is set to assess safety, tolerability and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously as compared to 60mg of the compound delivered intravenously in 16 healthy volunteers across four cohorts.

PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators -pharmacologically, it works as a non-competitive NMDA receptor antagonist- that holds the potential for rapid-acting antidepressant activity and anti-suicidal effects.

Although atai’s Phase 2a study on a single IV administration of 30mg and 60mg of PCN-101 in patients with Treatment-Resistant Depression didn’t reach the primary endpoint, it demonstrated “an encouraging safety profile and signals of efficacy across all time points out to two weeks, potentially indicating a sustained duration of effect,” says the company.

The present IV-to-subcutaneous bridging study, with expected completion in mid-2023, will potentially inform dosing regimens of the new subcutaneous formulation of PCN-101 for future studies, supporting further exploration of the potential of R-ketamine as a rapid-acting antidepressant for at-home use. (Full Story)

In categories:Psychedelics Research
Next Post

Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology. The open-label Phase 2 study tested psilocybin paired with psychological…
Read
Previous Post

Nevada Senators Approve Bill To Create Psychedelics Working Group To Plan For ‘Safe, Accessible And Affordable’ Access

Nevada lawmakers have approved a revised bill that would create a new working group to study psychedelics and develop a plan to allow regulated access for therapeutic purposes. While the legislation before the Senate Health and Human Services Committee as…
Read
Random Post

Does Smoking Cannabis Kill Your Brain Cells, Yes or No? Science Speaks!

As the legalization of recreational marijuana spreads across the United States, there is growing curiosity about its impact on the brain, including concerns about potential harm to brain cells. Just as the prolonged use of alcohol, methamphetamine, and heroin can lead to…
Read
Random Post

Cannabis Companies Sue U.S. Attorney General Over Federal Cannabis Laws

A group of Massachusetts-based cannabis companies are suing U.S. Attorney General Merrick Garland over federal cannabis laws, arguing the laws infringe on state powers, harms their business, and threatens the businesses’ safety because the laws force them to operate entirely in…
Read
Random Post

Big investors keener on cannabis MSOs as rescheduling looms, survey shows

Institutional investors are increasingly bullish on U.S. cannabis multistate operators, according to a new survey, which suggests marijuana rescheduling by the federal government could convince those big investors to put new money into MSOs. The group’s sentiment is “more bullish…
Read
Random Post

Why are the feds after Dan Bilzerian’s onetime marijuana company? His father has a theory.

If Dan Bilzerian had listened to his father and not taken his marijuana company public, the brash Instagram celebrity’s Ignite International Brands might not currently be under investigation by both the U.S. Securities and Exchange Commission and the Department of…
Read